According to DocCheck's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 7.76518. At the end of 2022 the company had a P/E ratio of 11.6.
Year | P/E ratio | Change |
---|---|---|
2022 | 11.6 | -14.49% |
2021 | 13.6 | 6.46% |
2020 | 12.8 | -12.44% |
2019 | 14.6 | -6.05% |
2018 | 15.5 | -24.45% |
2017 | 20.6 | 44.13% |
2016 | 14.3 | 21.75% |
2015 | 11.7 | -7.3% |
2014 | 12.6 | -35.29% |
2013 | 19.5 | 0% |
2012 | 19.5 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.